Pacific Biosciences of California, Inc. (PACB) analyst actions
Rating and price-target actions on PACB in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the PACB overview →
1 measured PACB analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million | Press release | -0.74% | +7.41% |
Keep exploring
More PACB: earnings → · SEC filings → · PACB overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BOVIE MEDICAL (BVX) | 441 | 0.00% | 46% |
| Catalyst Pharmaceuticals, Inc. (CPRX) | 441 | 0.00% | 50% |
| EyePoint, Inc. (EYPT) | 439 | -0.25% | 46% |
| Abeona Therapeutics Inc. (ABEO) | 438 | +0.09% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.